Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TdVax or IPOL in metastatic melanoma receiving checkpoint therapy
NCT05077137Phase 1Recruiting
- Sponsor
- Duke University
- Start
- Sep 2021
- Primary completion
- Jul 2027
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of diphtheria toxoid adsorbed + tetanus toxoid adsorbed and poliovirus vaccine in melanoma (2 arms), sponsored by Duke University. Primary endpoints: Number of subjects that successfully receive the vaccine after 4 cycles of IO therapy and Adverse Events. Started Sep 2021; status: recruiting.
02
Drugs
diphtheria toxoid adsorbed + tetanus toxoid adsorbedpoliovirus vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05077137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077137.